$Monte Rosa Therapeutics (GLUE.US)$ NEWS Monte Rosa Therapeu...
NEWS
Monte Rosa Therapeutics Presents Preclinical Data at Digestive Disease Week 2024 Highlighting Therapeutic Potential of MRT-6160 in Inflammatory Bowel Disease
Monte Rosa Therapeutics has presented preclinical data on their molecular glue degrader, MRT-6160, at Digestive Disease Week 2024. MRT-6160 targets VAV1, a protein involved in autoimmune and inflammatory diseases like colitis. The study showed significant results, including reduced disease progression by 85%, lowered colon inflammation, and decreased expression of IBD-associated genes in a murine model. The company plans to initiate a Phase 1 SAD/MAD study in mid-2024, with clinical data expected by Q1 2025. These findings suggest that MRT-6160 could offer a new therapeutic approach for treating inflammatory bowel disease.
Monte Rosa Therapeutics has presented preclinical data on their molecular glue degrader, MRT-6160, at Digestive Disease Week 2024. MRT-6160 targets VAV1, a protein involved in autoimmune and inflammatory diseases like colitis. The study showed significant results, including reduced disease progression by 85%, lowered colon inflammation, and decreased expression of IBD-associated genes in a murine model. The company plans to initiate a Phase 1 SAD/MAD study in mid-2024, with clinical data expected by Q1 2025. These findings suggest that MRT-6160 could offer a new therapeutic approach for treating inflammatory bowel disease.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
840Followers
62Following
5574Visitors
Follow